[1] Zuo TT,Zheng RS,Zhang SW,et al.Incidence and mortality of liver cancer in China in 2010. Chin J Can,2015, 15:34:508-513.
[2] Wang JP,Kao FY,Wu CY,et al.Nucleos(t)ide analogues associated with a reduced risk of hepatocellular carcinoma in hepatitis B patients:a population-based cohort study.Cancer,2015,1:121:1446-1455.
[3] Wu CY,Lin JT,Ho HJ,et al.Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nationwide cohort study.Gastroenterol,2014,147:143-151.
[4] Wei L,Kao JH.Benefits of long-term therapy with nucleos(t)ide analogues in treatment-na?ve patients with chronic hepatitis B,Curr Med Res Opin,2017,33:495-504.
[5] Ando Y,Ishigami M,Ishizu Y,et al.Cumulative incidence and risk factors for the development of hepatocellular carcinoma in patients with chronic hepatitis B who achieved sustained disappearance of viremia by nucleos(t)ide analog treatment.Hepatol Res,2018,48:E240-E251.
[6] Hiramatsu N,Yamada R,Takehara T.The suppressive effect of nucleos(t)ide analogue treatment on the incidence of hepatocellular carcinoma in chronic hepatitis B patients.J Gastroenterol Heaptol,2016,31:546-552.
[7] Surveillance group, Diagnosis group, Staging group,et al.Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan.J Formos Med Assoc,2018,117:381-403.
[8] Levrero M,Subic M,Villeret F,et al.Perspectives and limitations for nucleo(t)side analogs in future HBV therapies.Curr Opin Virol,2018,30:80-89.
[9] Jang JW,Choi JY,Kim YS,et al.effects of virologic response to treatment on short-and long-term outcomes of patients with chronic HBV infection and decompensated cirrhosis.Clin Gastroenterol Hepatol,2018, 16:1954-1963.
[10] Loqlio A,lavarone M,Grossi G,et al.Clinical features and outcomes of hepatocellular carcinoma in Caucasian cirrhotic patients on long-term analogue therapy for hepatitis B.Aliment Parmacol Ther,2018 ,48:431-439.
[11] Budhu A, Wang XW.The role of cytokines in hepatocellular carcinoma. J Leukoc Biol,2006,80:1197-1213.
[12] Ma KW, Cheung TT. Surgical resection of localized hepa-tocellular carcinoma: patient selection and special consideration.J Hepatocell Carcinoma,2016,28:1-9.
[13] Piscaglia F,Ogasawara S.Patient selection for transarterial chemoebolization in hepatocellular carcinoma:importance of benefit/risk assessment.Liver Cancer,2018,7:104-119.
[14] Hu h,Chen GF,Yuan W,et al.Microwae ablation with chemoembolization for large hepatocellular carcinoma in patients with cirrhosis.Int J Hyperthermia,2018,34:1351-1358. |
